Alector Therapeutics mentioned Monday that its Section 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what had been one of many main darkish horse approaches to treating the neurodegenerative illness.
The drug, known as AL002, is designed to activate a gaggle of surveilling neuronal immune cells known as microglia. It was amongst a number of efforts, now in or nearing medical trials, predicated on the notion that modulating the mind’s immune system might gradual the degenerative illness.
Within the 381-person trial, nevertheless, sufferers who acquired AL002 didn’t decline extra slowly than sufferers who have been on placebo, as measured by a scale known as the Medical Dementia Score Sum of Bins. Alector mentioned the trial additionally failed to point out an impact on secondary measures of cognition and performance, or on biomarkers related to the illness, corresponding to amyloid ranges.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
View All Plans
